KaloBios Pharmaceuticals, founded with a mission to advance biopharmaceutical solutions for rare diseases and specific cancers, focuses on developing proprietary, targeted monoclonal antibodies. Their core vision is to significantly improve the care of seriously ill patients through innovative science. The company offers a pipeline of first-in-class monoclonal antibodies designed to address unmet medical needs in oncology, aiming to provide better life through better science.
Notable figures affiliated with KaloBios include industry experts in biopharmaceutical development and oncology research. The company has garnered attention for its significant achievements, such as FDA clearance for investigational new drug applications. KaloBios' impact is marked by its dedication to transforming patient care in the oncology sector, striving to bring advanced treatments to market for neglected and rare diseases.
